Repligen(NASDAQ) RGEN

Repligen Corporation NASDAQ:RGEN makes tools used to manufacture biological medicines. These tools help drug companies create treatments for many diseases. They help make drug production faster and more efficient.

Essential Bioprocessing Technologies

• Filtration products: Filters used to concentrate and purify biological drugs; accounted for $95.7 million of product revenue in the three months ended June 30, 2026.
• Chromatography products: Tools such as pre-packed columns and resins for protein separation; generated $51.9 million of product revenue in the three months ended June 30, 2026.
• Process analytics products: Systems providing real-time data to monitor production; contributed $25.8 million of product revenue in the three months ended June 30, 2026.
• Proteins products: Binding elements and growth factors for biomanufacturing; provided $31.4 million of product revenue in the three months ended June 30, 2026.

Strategic Deals and Shifts

• Entered an agreement to acquire BioLife Solutions for approximately $1.5 billion in July 2026.
• Completed the acquisition of 908 Devices' desktop bioprocessing portfolio in March 2025.
• Divested the Polymem business in March 2026 to focus on core operations.

Bridging the Manufacturing Gap

Repligen maintains a broad portfolio serving both upstream and downstream manufacturing steps. Its systems integrate into existing workflows to improve flexibility and yield for drug developers.

Financial Performance Data

• Total revenue reached $204.1 million in the three months ended June 30, 2026, up 11.9% year over year.
• Gross margin increased to 53.9% in the three months ended June 30, 2026, compared to 51.0% in the same period in 2025.
• Cash provided by operating activities was $61.1 million for the six-month period ended June 30, 2026.
• Total liquidity reached $810.4 million as of June 30, 2026.

Evolution of the Business

Repligen has transitioned into a comprehensive provider of bioprocessing technologies through strategic acquisitions and internal innovation. This evolution allows it to support the entire production cycle of modern biological medicines.